We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 294

Oder of prohibition issues no promise to treatment in humans or reduced side effects was found
  • Borden Ladner Gervais LLP
  • Canada
  • April 30 2014

Pfizer’s Canadian Patent No. 2,177,576 for Celebrex has withstood Apotex’s allegations and was found to be valid; therefore the Minister is


Court of Appeal upholds decision awarding Section 8 compensation where sales related to “unauthorized indications” Sanofi-Aventis Canada Inc. v. Teva Canada limited, 2014 FCA 69
  • Borden Ladner Gervais LLP
  • Canada
  • March 24 2014

Drug: ramipril This was an appeal by Sanofi-Aventis Canada Inc. and Sanofi-Aventis Deutschland GmbH (collectively "Sanofi") from a judgment of the


Question remitted to the court a second time for redetermination
  • Borden Ladner Gervais LLP
  • Canada
  • October 25 2012

The Court of Appeal remitted a case to the Court, requiring the Court to redetermine whether Corlac had infringed a method claim by inducement


Court of Appeal considers comity as it applies to NOC proceedings
  • Borden Ladner Gervais LLP
  • Canada
  • December 4 2012

Apotex v


Supreme Court denies Apotex leave to appeal; prohibition order stands
  • Borden Ladner Gervais LLP
  • Canada
  • April 30 2014

The Supreme Court of Canada (SCC) denied Apotex leave to Appeal the decision of the Federal Court of Appeal (FCA) in a s. 8 case (decision here


Order of Prohibition granted for one patent due to insufficiency of NOA
  • Borden Ladner Gervais LLP
  • Canada
  • October 16 2012

This is a proceeding commenced under the Patented Medicines (Notice of Compliance) Regulations, seeking an order to prohibit the Minister of Health from issuing a notice of compliance to Mylan for efavirenz, an anti-retroviral drug used to treat HIV infection


Appeal of prohibition order dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • October 21 2013

The Federal Court issued an order prohibiting Teva from entering the market with its version of zoledronic acid until the expiration of two patents


ss. 53(2) of the Patent Act is a shield, not a sword
  • Borden Ladner Gervais LLP
  • Canada
  • October 21 2013

Hoffmann-La Roche was denied the opportunity to correct a single word error in a patent’s disclosure pursuant to ss.53(2) of the Patent Act. The


Intellectual property weekly abstract bulletin - week of 7th October 2013
  • Borden Ladner Gervais LLP
  • Canada
  • October 7 2013

The Federal Court has dismissed an application to prohibit the Minister of Health from issuing a Notice of Compliance to the Respondent Cobalt in


Evidence struck and reply granted after partial reversal
  • Borden Ladner Gervais LLP
  • Canada
  • October 21 2013

In this case, there was an Order for partial reversal of evidence. Apotex brought a motion to strike substantial portions of the affidavits of three